EQS-News: BB Biotech AG: End of year biotech equity market rally – M&A and end of rate hike cycle
Media release as at January 19, 2024
- Media release as at January 19, 2024
Portfolio of BB Biotech AG as at December 31, 2023
In 2023, global equity performed better than anticipated by many. - Consequently, BB Biotech ended the year with a net loss of CHF 207 mn.
- This represents a 5% return based on the volume-weighted average closing price of BB Biotech shares in December 2023.
- The US central bank held rates steady in the fall, lifting market sentiment in the last two months of 2023.